The anticancer drug FZ has been shown to induce apoptosis and suppress tumor growth in a variety of cancer cell models. The drug targets a number of proteins and genes to promote cancer cell death. It inhibits the expression of GLUT transporters and HK II, key glycolytic enzymes. FZ treatment also reduces glucose uptake by cancer cells.
Fenbendazole is a broad-spectrum anthelmintic, which means it is effective against most types of roundworms. This type of anthelmintic has been used as a veterinary medicine for almost 50 years. In humans, the drug has not been studied extensively, but there have not been any major side effects reported. However, it should be noted that fenben lab is still not FDA-approved for use in humans.
In recent years, researchers have started to investigate whether Fenben can be effective in treating animal cancer. Although a number of studies have been performed on animals, the results have not been conclusive. However, the research has shown that FZ is effective against colon cancer cells in a mouse model.
In a study of NSCLC cells, FZ induced a decrease in glucose uptake and oxidation. This inhibitory effect was also associated with cell death, which was found to be a potential side effect of FZ treatment. These results indicate that FZ may be a viable therapeutic option for cancer patients.
In vitro studies on FZ, treatment with FZ inhibits the growth of A549 cells. When administered orally, FZ reduced the size of colons and anchorage-independent growth in A549 cells. This reduction was also seen in the soft agar assay. Moreover, FZ treatment also reduced tumor vascularity, an indicator of reduced tumor growth.
However, a fluorescence-based competitive colchicine binding assay showed that FZ does not alter the amount of acetylation of tubulin in human cells. These results suggest that FZ inhibits the growth of cancer cells by depolymerizing microtubules and re-shaping them into tubulin subunits.